Drug Trial Radar · NCT04390737
Evaluate the Safety and Clinical Activity of HH2853
Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
254
Planned (sponsor's estimate)
Start
Sep 8, 2020
Primary completion
Dec 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Haihe Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 15, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.
Conditions
- FL Lymphoma
- Epithelioid Sarcoma
- Peripheral T Cell Lymphoma
- Advanced Solid Tumor
Interventions
HH2853 TabletsDrug
Proposed daily dose (BID): 50mg, 100mg, 200mg, 400mg, 600mg, 800mg, 1000mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the MTD in order to better understand safety, PK or PD.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated Dose (MTD)Time frame: 28-day treatment cycles
- Recommended phase II dose (RP2D)Time frame: 28-day treatment cycles
- Adverse events assessed according to NCI-CTCAE V5.0Time frame: 28-day treatment cycles
- Dose limiting toxicities (DLT)Time frame: 28-day treatment cycles
- Objective response rate (ORR)Time frame: 28-day treatment cycles
Locations
25 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic
Phoenix, Arizona · Completed
Mayo Clinic
Jacksonville, Florida · Completed
Mayo Clinic
Rochester, Minnesota · Completed
NEXT Oncology
San Antonio, Texas · Completed
Beijing Cancer Hospital
Beijing, China · Recruiting
Sun Yat-Sen University Cancer Hospital
Guangzhou, China · Recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Beijing Jishuitan Hospital
Beijing, Beijing Municipality, China · Recruiting
Sun Yat-Sen University Cancer Hospital
Guangzhou, Guangdong, China · Recruiting
Affiliated Tumor Hospital of Guangxi Medical University
Nanning, Guangxi, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Affiliated Drum Tower Hospital, Medical School of Nanjing University
Nanjing, Jiangsu, China · Recruiting
Liaoning Cancer Hospital&Institute
Shenyang, Liaoning, China · Recruiting
Shengjing Hospital Of China Medical University
Shenyang, Liaoning, China · Recruiting
Linyi Tumor Hospital
Linyi, Shandong, China · Recruiting
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Shanxi Cancer Hospital
Taiyuan, Shanxi, China · Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.